Last reviewed · How we verify

MDR-101 — Competitive Intelligence Brief

MDR-101 (MDR-101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy. Area: Pulmonology / Rare Genetic Lung Disease.

phase 3 Gene therapy ABCA3 gene Pulmonology / Rare Genetic Lung Disease Biologic Live · refreshed every 30 min

Target snapshot

MDR-101 (MDR-101) — Medeor Therapeutics, Inc.. MDR-101 is a gene therapy that delivers a functional copy of the ABCA3 gene to restore surfactant production in patients with ABCA3-deficient interstitial lung disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MDR-101 TARGET MDR-101 Medeor Therapeutics, Inc. phase 3 Gene therapy ABCA3 gene
rAd-p53 gene rAd-p53 gene Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy; oncolytic virus p53 tumor suppressor gene
voretigene neparvovec-rzyl voretigene neparvovec-rzyl Spark Therapeutics, Inc. marketed Gene therapy RPE65 gene
Onasemnogene Abeparvovec-brve Onasemnogene Abeparvovec-brve Novartis Pharmaceuticals marketed Gene Therapy SMN1 gene
p53 gene with surgery p53 gene with surgery Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy (p53 tumor suppressor) p53 (tumor protein p53)
Onasemnogene Abeparvovec-xioi Onasemnogene Abeparvovec-xioi Novartis Gene Therapies marketed Gene therapy SMN1 gene
chemotherapy plus p53 chemotherapy plus p53 Shenzhen SiBiono GeneTech Co.,Ltd marketed Combination chemotherapy with p53 gene therapy p53 tumor suppressor protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy class)

  1. Spark Therapeutics, Inc. · 4 drugs in this class
  2. MeiraGTx UK II Ltd · 3 drugs in this class
  3. Novartis Gene Therapies · 2 drugs in this class
  4. Kolon TissueGene, Inc. · 2 drugs in this class
  5. Krystal Biotech, Inc. · 2 drugs in this class
  6. Abeona Therapeutics, Inc · 2 drugs in this class
  7. Larimar Therapeutics, Inc. · 1 drug in this class
  8. 4D Molecular Therapeutics · 1 drug in this class
  9. Medeor Therapeutics, Inc. · 1 drug in this class
  10. MeiraGTx, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MDR-101 — Competitive Intelligence Brief. https://druglandscape.com/ci/mdr-101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: